James W Hodge

List of Publications by Year
in descending order

138	12,924	23567	27406
papers	citations	58 h-index	106 g-index

163	163	163	13034
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. Journal of Experimental Medicine, 2006, 203, 1259-1271.	8.5	1,389
2	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
3	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
4	Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes. Cancer Research, 2004, 64, 7985-7994.	0.9	489
5	Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy. Journal of Immunology, 2003, 170, 6338-6347.	0.8	429
6	External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing. Cancer Research, 2004, 64, 4328-4337.	0.9	410
7	Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer. Clinical Cancer Research, 2005, 11, 3353-3362.	7.0	357
8	Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget, 2014, 5, 403-416.	1.8	331
9	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	4.8	317
10	Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. Nature Reviews Clinical Oncology, 2016, 13, 516-524.	27.6	288
11	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunology, Immunotherapy, 2010, 59, 663-674.	4.2	279
12	Chemotherapyâ€induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International Journal of Cancer, 2013, 133, 624-636.	5.1	225
13	Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma. Clinical Cancer Research, 2008, 14, 3060-3069.	7.0	208
14	Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement. Clinical Cancer Research, 2008, 14, 3536-3544.	7.0	207
15	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opinion on Investigational Drugs, 2009, 18, 1001-1011.	4.1	187
16	Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine, 1997, 15, 759-768.	3.8	170
17	Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. Journal of Translational Medicine, 2014, 12, 294.	4.4	144
18	An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget, 2016, 7, 86359-86373.	1.8	143

#	Article	IF	Citations
19	IL-15 superagonist/IL-15RÎ±Sushi-Fc fusion complex (IL-15SA/IL-15RÎ±Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget, 2016, 7, 16130-16145.	1.8	138
20	The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors. Seminars in Oncology, 2012, 39, 323-339.	2.2	132
21	Multiple Costimulatory Modalities Enhance CTL Avidity. Journal of Immunology, 2005, 174, 5994-6004.	0.8	128
22	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clinical Cancer Research, 2020, 26, 4268-4279.	7.0	126
23	Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC. Journal of Immunology, 2003, 170, 2523-2530.	0.8	120
24	Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cellâ€“Mediated Killing. International Journal of Radiation Oncology Biology Physics, 2016, 95, 120-130.	0.8	117
25	Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. International Journal of Cancer, 2012, 130, 1948-1959.	5.1	115
26	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. Cancer Immunology Research, 2014, 2, 133-141.	3.4	115
27	Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncology, 2019, 95, 127-135.	1.5	103
28	Abscopal Regression of Antigen Disparate Tumors by Antigen Cascade After Systemic Tumor Vaccination in Combination with Local Tumor Radiation. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 12-22.	1.0	101
29	A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate. International Journal of Cancer, 1995, 63, 231-237.	5.1	99
30	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget, 2016, 7, 37762-37772.	1.8	96
31	Acquisition of CD80 (B7-1) by T Cells. Journal of Immunology, 2001, 166, 2505-2513.	0.8	95
32	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. OncoImmunology, 2018, 7, e1395996.	4.6	90
33	In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Frontiers in Oncology, 2012, 2, 104.	2.8	89
34	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget, 2016, 7, 7390-7402.	1.8	89
35	Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis. Clinical Cancer Research, 2006, 12, 1897-1905.	7.0	85
36	In VivoEffects of Lattice Radiation Therapy on Local and Distant Lung Cancer: Potential Role of Immunomodulation. Radiation Research, 2014, 182, 149-162.	1.5	85

#	Article	IF	Citations
37	Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget, 2016, 7, 33498-33511.	1.8	85
38	Vaccine therapy of established tumors in the absence of autoimmunity. Clinical Cancer Research, 2003, 9, 1837-49.	7.0	83
39	The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor) Tj ETQq1 1 0.784314 rgBT /Ov	7.0	79
40	Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses. Clinical Cancer Research, 2005, 11, 2416-2426.	7.0	79
41	PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. , 2020, 8, e000450.		79
42	Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Research, 2002, 62, 5770-7.	0.9	79
43	Vaccination with a Recombinant Saccharomyces cerevisiae Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses. Clinical Cancer Research, 2008, 14, 4316-4325.	7.0	76
44	Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?. Molecular BioSystems, 2009, 5, 1262.	2.9	75
45	Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model. Clinical Cancer Research, 2013, 19, 6205-6218.	7.0	75
46	Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. Cancer Immunology Research, 2016, 4, 611-620.	3.4	73
47	Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology, 2008, 22, 1064-70; discussion 1075, 1080-1, 1084.	0.5	72
48	Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 153-161.	1.0	71
49	Vaccines based on whole recombinant Saccharomyces cerevisiae cells. FEMS Yeast Research, 2010, 10, 1060-1069.	2.3	69
50	Therapeutic Cancer Vaccines. Advances in Cancer Research, 2014, 121, 67-124.	5.0	68
51	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget, 2017, 8, 8807-8817.	1.8	68
52	Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunology, Immunotherapy, 2011, 60, 1227-1242.	4.2	66
53	Cancer Vaccines: Preclinical Studies and Novel Strategies. Advances in Cancer Research, 2006, 95, 115-145.	5.0	64
54	The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cellâ€“Mediated Killing. Clinical Cancer Research, 2008, 14, 4241-4249.	7.0	64

#	Article	IF	Citations
55	Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget, 2014, 5, 9335-9348.	1.8	64
56	From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 728018.	2.8	63
57	Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget, 2013, 4, 1777-1790.	1.8	63
58	Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomasâ€™ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget, 2016, 7, 86937-86947.	1.8	63
59	Anti-Tumor Immunity Elicited by a Recombinant Vaccinia Virus Expressing CD70 (CD27L). Human Gene Therapy, 1999, 10, 1095-1103.	2.7	62
60	Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines. Cancer Immunology Research, 2014, 2, 1090-1102.	3.4	62
61	Unlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy. Radiation Research, 2014, 182, 126-138.	1.5	62
62	Immune Consequences of Tyrosine Kinase Inhibitors that Synergize with Cancer Immunotherapy. Cancer Cell & Microenvironment, 2015, 2, .	0.8	61
63	Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine, 2008, 26, 509-521.	3.8	60
64	Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity. Journal of Immunology, 2013, 190, 6250-6258.	0.8	59
65	Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunology, Immunotherapy, 1996, 43, 127-134.	4.2	58
66	Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression. PLoS ONE, 2013, 8, e70417.	2.5	57
67	Enhancing immune responses to tumor-associated antigens. Cancer Biology and Therapy, 2009, 8, 1440-1449.	3.4	56
68	Immunotherapy utilizing the combination of natural killerâ€“ and antibody dependent cellular cytotoxicity (ADCC)â€“mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. , 2018, 6, 133.		56
69	Harnessing the Potential of Radiation-Induced Immune Modulation for Cancer Therapy. Cancer Immunology Research, 2013, 1, 280-284.	3.4	55
70	An IL-15 superagonist/IL-15RÎ± fusion complex protects and rescues NK cell-cytotoxic function from TGF-Î²1-mediated immunosuppression. Cancer Immunology, Immunotherapy, 2018, 67, 675-689.	4.2	55
71	Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Research, 2003, 63, 7942-9.	0.9	55
72	TRICOM Vector Based Cancer Vaccines. Current Pharmaceutical Design, 2006, 12, 351-361.	1.9	53

#	Article	IF	Citations
73	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. OncoImmunology, 2018, 7, e1466018.	4.6	51
74	Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF. Clinical Cancer Research, 2013, 19, 1290-1299.	7.0	50
75	Costimulatory Molecules as Adjuvants for Immunotherapy. Frontiers in Bioscience - Landmark, 2006, 11, 788.	3.0	49
76	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigenâ€“Specific T Cells. Clinical Cancer Research, 2020, 26, 679-689.	7.0	49
77	PART V. Modulation of Antitumor Vaccine StrategiesPreclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy. Critical Reviews in Immunology, 2007, 27, 451-462.	0.5	49
78	Construction and Characterization of a Recombinant Vaccinia Virus Expressing Murine Intercellular Adhesion Molecule-1: Induction and Potentiation of Antitumor Responses. Human Gene Therapy, 1997, 8, 851-860.	2.7	46
79	Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 705-709.	3.1	46
80	Vaccines with Enhanced Costimulation Maintain High Avidity Memory CTL. Journal of Immunology, 2005, 175, 3715-3723.	0.8	45
81	Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. OncoImmunology, 2014, 3, e28643.	4.6	44
82	Natural Born Killers: NK Cells in Cancer Therapy. Cancers, 2020, 12, 2131.	3.7	44
83	Overcoming hypoxia-induced functional suppression of NK cells. , 2020, 8, e000246.		44
84	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. , 2018, 6, 59.		43
85	Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunology, Immunotherapy, 2008, 57, 1173-1183.	4.2	41
86	Effect of a small molecule BCLâ€2 inhibitor on immune function and use with a recombinant vaccine. International Journal of Cancer, 2010, 127, 1603-1613.	5.1	41
87	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1749-58.	7.1	41
88	Combining radiation and immunotherapy for synergistic antitumor therapy. Current Opinion in Molecular Therapeutics, 2009, 11, 37-42.	2.8	41
89	Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight, 2019, 4, .	5.0	40
90	Intratumoral Vaccination and Diversified Subcutaneous/ Intratumoral Vaccination with Recombinant Poxviruses Encoding a Tumor Antigen and Multiple Costimulatory Molecules. Clinical Cancer Research, 2004, 10, 1090-1099.	7.0	39

#	Article	IF	Citations
91	Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunology, Immunotherapy, 2010, 59, 397-408.	4.2	39
92	The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Molecular Therapy - Oncolytics, 2021, 23, 266-276.	4.4	38
93	ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. International Journal of Cancer, 2017, 141, 583-593.	5.1	37
94	Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 23-35.	1.0	36
95	Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Therapy, 2004, 11, 665-680.	4.6	35
96	Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Research, 2002, 62, 5058-64.	0.9	35
97	Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. , 2021, 9, e001691.		34
98	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget, 2015, 6, 31344-31359.	1.8	32
99	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. ELife, 2020, 9, .	6.0	32
100	Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process. Cancer Research, 2014, 74, 1945-1957.	0.9	31
101	Combination Regimens of Radiation Therapy and Therapeutic Cancer Vaccines: Mechanisms and Opportunities. Seminars in Radiation Oncology, 2015, 25, 46-53.	2.2	30
102	Attacking malignant cells that survive therapy. OncoImmunology, 2013, 2, e26937.	4.6	29
103	Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. Vaccine, 2009, 27, 4475-4482.	3.8	28
104	A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 enhanced cytokine production. Cellular Immunology, 2003, 222, 45-57.	3.0	27
105	Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. Oral Oncology, 2017, 71, 87-94.	1.5	26
106	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. Clinical Cancer Research, 2020, 26, 704-716.	7.0	26
107	A poxviral-based cancer vaccine targeting the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model. Oncotarget, 2015, 6, 28194-28210.	1.8	26
108	Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin. Oncotarget, 2016, 7, 23498-23511.	1.8	25

#	Article	IF	Citations
109	Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2. Clinical Cancer Research, 2007, 13, 1936-1946.	7.0	23
110	Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. , 2015, 3, 52.		22
111	Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detection and Prevention, 2002, 26, 275-291.	2.1	19
112	Hadley J. Sharp, Elizabeth K. Wansley, Charlie T. Garnett, Mala Chakraborty, Kevin Camphausen, Jeffrey Schlom, James W. Hodge. Frontiers in Bioscience - Landmark, 2007, 12, 4900.	3.0	19
113	Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. Expert Review of Vaccines, 2013, 12, 617-629.	4.4	18
114	Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer. Oncotarget, 2017, 8, 90825-90841.	1.8	18
115	ABO blood type correlates with survival on prostate cancer vaccine therapy. Oncotarget, 2015, 6, 32244-32256.	1.8	18
116	Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. Vaccine, 2017, 35, 2605-2611.	3.8	17
117	A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. Journal of Neurosurgery, 2018, 128, 1419-1427.	1.6	17
118	Prostate-specific antigen bounce predicts for aÂfavorable prognosis following brachytherapy: aÂmeta-analysis. Journal of Contemporary Brachytherapy, 2013, 4, 210-214.	0.9	14
119	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines, 2021, 9, 509.	4.4	14
120	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. Journal of Clinical Oncology, 2013, 31, 102-102.	1.6	14
121	General Keynote: Vaccine Strategies for the Therapy of Ovarian Cancer. Gynecologic Oncology, 2003, 88, S97-S104.	1.4	13
122	Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. , 2021, 9, e002258.		11
123	Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immuneâ€“Tumor Interactions: Engage, Expand, Enable. Cancer Immunology Research, 2021, 9, 239-252.	3.4	11
124	Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel.. Journal of Clinical Oncology, 2012, 30, 2526-2526.	1.6	11
125	A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines. Vaccine, 2014, 32, 3223-3231.	3.8	10
126	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. Cancers, 2021, 13, 968.	3.7	9

#	Article	IF	Citations
127	Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. International Journal of Cancer, 2000, 85, 508-517.	5.1	8
128	Combinatorial Natural Killer Cellâ€“based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells. Cancer Research Communications, 2021, 1, 127-139.	1.7	8
129	Next Generation Therapeutic Strategâ€Es: Evolving cancer immunotherapy through agents that Engage , Expand and Enable the antiâ€tumor immune response. Immunomedicine, 2021, 1, e1020.	0.7	6
130	Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy. OncoImmunology, 2015, 4, e1009303.	4.6	5
131	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5096-TPS5096.	1.6	3
132	Cancer vaccine development. Expert Opinion on Investigational Drugs, 1998, 7, 1439-1452.	4.1	2
133	Recombinant TRICOM-based Therapeutic Cancer Vaccines. , 2013, , 309-331.		1
134	Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. , 2014, , .		1
135	The IDO inhibitor INCB024360 to enhance dendritic cell immunogenicity and anti-tumor immunity in vitro.. Journal of Clinical Oncology, 2015, 33, e14012-e14012.	1.6	1
136	Design, development, and translation of poxvirus-based vaccines for cancer. , 2011, , 56-77.		1
137	Combining radiation and therapeutic cancer vaccines: a synergistic approach. Breast Cancer Management, 2012, 1, 325-335.	0.2	0
138	Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition.. Journal of Clinical Oncology, 2018, 36, 5021-5021.	1.6	0